ImmunityBio is conducting trials of Anktiva in various cancers, including NSCLC and ovarian cancer. Click here to read an analysis of IBRX stock now.

Although the use of intravesical immunotherapy for reducing tumor progression or as maintenance therapy is controversial, bacillus Calmette–Guérin has demonstrated significant benefit for tumor ...

Associated Medical Professionals of NY, Urology of Indiana and Central Ohio Urology Group are the latest three US-based study sites for clinical research of Theralase®'s bladder cancer treatment ...

LUGPA annual meeting, Gautam Jayram, MD, reviewed important developments therapeutics and diagnosis and staging.

Protara stock surges 70% as investigational cell therapy, TARA-002, shows superior six-month efficacy in phase II bladder ...

Up to 112,800 ordinary shares of UroGen are issuable upon the vesting and settlement of the RSUs. The RSUs will vest equally over three years, with one-third of the underlying shares vesting each year ...

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specia ...

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that ...

A Mayo Clinic Comprehensive Cancer Center researcher will share findings from a late-breaking abstract at the 2024 Society of ...

Protara Therapeutics reports promising Phase 2 results for TARA-002 in bladder cancer patients, highlighting high response rates and strong safety data.

TARA-002 demonstrates 72% six-month landmark complete response rate and 70% complete response rate at any time across BCG exposures100% six-month ...

The Study Procedure is comprised of the intravesical installation of reconstituted Ruvidar TM for 1 hour, followed by TLC-3200 intravesical activation for approximately 1 hour. To date, Theralase® has ...